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INTRODUCTION 
  Prostate cancer is one amongst the most common medical diseases affecting 
elderly men. Carcinoma of the prostate is being the most common non-cutaneous 
cancer diagnosed in American male population. The lifetime risk of prostatic 
carcinoma is 16.7 % and the risk of death
 
during the entire lifetime is around 2.6% 
for men in United States but the overall lifetime risk of death due to prostate 
malignancy is low in comparison to lifetime risk of diagnosis.  
In developed countries carcinoma of the prostate gland is more common in 
the elderly male population compared with younger men. Around 15% of men 
diagnosed to have cancer of the prostate in developed world when compared to 
only about 4% of men in developing nations. 
 The association of cancer prostate and serum testosterone is known for the 
past few decades. The benefits of surgical castration and the role of estrogen 
treatment on the management of metastatic cancer prostate was assessed since 
olden days (Huggins and Hodges, 1941).They earlier demonstrated the clinical 
beneficial effects of androgen suppression therapy in the management of metastatic 
(advanced) cancer prostate. 
 The androgen suppression benefits are recently extended in the management 
of even in non metastatic prostate cancer patients and recurrent prostate cancer 
after definitive management. Again there is a role for hormonal therapy in 
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neoadjuvant settings like before radical prostatectomy which resulted in decrease 
in serum PSA, Shrinkage of prostate tumor volume and reduction in the rate of 
positive surgical margins. The reduction in prostate volume following neoadjuvant 
hormonal therapy is more in peripheral zone compared to central zone. 
Prostate cancer is a hormone dependant cancer and the clinical course of 
prostate cancer varies with individual and again it varies within the individual in 
relationship to serum testosterone levels. The present study is to find out the role of 
low serum testosterone level in predicting prostate cancer behaviour in comparison 
with normal serum testosterone level patients and to find out the relationship 
between low serum testosterone level and serum PSA levels in TRUS biopsy 
proven cancer prostate patients. 
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AIM AND OBJECTIVES 
 
 
 
The primary aim and objective of our study is to determine the association of low 
serum testosterone and prostate cancer behaviour and with a Secondary objective 
to determine the relationship of serum PSA level  in cancer prostate patients with 
low serum testosterone.  
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REVIEW OF LITERATURE 
Anatomy of the prostate gland: 
Zonal Anatomy: 
 The prostate gland is analogous to the shape of an inverted pear with broader 
base of the prostate located cranially and the narrow prostatic apex caudally. The 
prostatic gland is composed of 15 to 30 branched tubuloalveolar glands which in 
turn embedded in a stroma of connective tissue and smooth muscles. 
 The prostatic glands are outgrowths of the mucous membrane of the urethra, 
ends in excretory ducts which in turn open into the prostatic urethra at and below 
the level of verumontanum. The paired ejaculatory ducts also open into the 
prostatic urethra at verumontanum level. The ejaculatory duct is formed by the 
union of the ampulla of the ductus deferens and Seminal vesicle duct just before 
terminates into the posterior aspect of the base of the prostate. 
 The prostate gland is distinguished into three glandular regions namely a 
central zone, a transition (periurethral) zone, and a peripheral zone
2
. 
 In young male population the peripheral zone occupies 70-75% of the total 
prostatic volume and the central zone occupies 25% and nearly 5% of the gland by 
the transition zone. 
  
 5 
The zonal composition changes with age. The central zone is more in young men 
and as the age advances it undergoes progressive atrophy and sometime reduction 
in size of the gland but in most men there is overall increase in prostatic glandular 
size due to benign prostatic hypertrophy involving transition zone. The peripheral 
zone is most important site of origin of prostate cancer. 
 The central zone is composed mainly of stoma and compact smooth muscle 
bundles but the peripheral zone smooth muscle bundles are loosely arranged with 
abundant glandular component. The peripheral zone is located along the lateral and 
posterior aspect of the prostatic gland surroundings the central zone. 
The central zone is embedded between the anteriorly placed transition zones 
and postero-laterally placed peripheral zone. 
At the level of verumontanum, the urethra makes an age of 35°. The distal 
prostatic portion of urethra is in close contact with the periurethral glands and 
preprostatic sphincter. 
The preprostatic sphincter is formed by the striated muscles and surrounds 
the proximal portion of the prostatic urethra between the base of the 
verumontanum and the bladder neck area. The zonal anatomy of prostate gland is 
as shown in figure 1. 
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Figure 1.zonal anatomy of prostate gland. 
The distal prostatic urethra is surrounded by striated muscle bundle which 
merge distally beyond the apex of the prostate gland with external sphincter.  
The anterior fibromuscular stroma mainly composed of smooth muscles 
blends with the muscle fibers at bladder neck and surrounds the urethra, the 
anterior muscle fibers extends from the bladder neck and spreads laterally and 
covers the entire anterior and antero lateral aspect of the prostate gland. 
The prostate gland is enclosed by capsule about 1 mm in diameter which 
consists of fibromuscular strands and extends into the pubovesical ligments and 
muscles. The fibromuscular strands which surround the prostate are an intrinsic 
and inseparable part of the prostate gland which is incompletely formed at the 
apex. 
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NEURO VASCULAR ANATOMY: 
 The arterial supply of the prostate gland originates from inferior Vesical 
artery and middle hemorrhoidal branches of the internal iliac artery. 
 The veins from prostatic plexus which covers the gland more on the lateral 
aspect. The prostatic venous plexus communicates with hemorrhoidal plexus 
posteriorly and with vesical venous plexus and venous plexus of Santorini’s 
superiorly and drain into the internal iliac veins. The nerve supply are derived from 
pelvic plexus and is distributed mainly to connective tissue around the gland. The 
Neurovascular bundles NVBs are most important periprostatic structures which 
consist of sympathetic nerves, arteries and veins of the prostate gland. The paired 
NVBs runs along the postero lateral aspect of the prostate and gives periodical 
branches which pierces the prostatic capsule to reach the prostate gland.
 
 
The surgical anatomy of the prostate gland is depicted in the figure 2. 
  
Figure 2. Surgical anatomy of prostate gland. 
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The extra capsular spread of prostate cancer occurs along the sites of 
penetrating branches of NVBs into the prostate capsule.
 
While performing “Nerve 
Sparing” radical prostatectomy, the surgeon aims to preserve potency by sparing 
one or both NVBs. 
LYMPHATIC DRAINAGE: 
 The Lymphatic drainage of the prostate gland is rich and forms a network 
over the posterior aspect of the prostate. The lymphatic from this posterior surface 
drains into the internal iliac group of nodes and the “obturator nodes” of the 
external lymphatic chain. 
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PROSTATE CARCINOMA: 
EPIDEMIOLOGY: 
 Cancer of the prostate gland is a major public health problem in men aged 
40 years and above and is comparable with that of women with breast Cancer. The 
Prostate Carcinoma is the most common cancer in American men (excluding skin 
carcinoma) and is the second in the list of common cancers in men. 
The median age at the time of cancer prostate diagnosis is around 68 and 
more than 60% of carcinoma prostate is made above the age of 65. There is a 
significant variation in the geographic distribution of prostate cancer incidence. 
The serum Prostatic Specific Antigen (PSA) testing has revolutionized the 
prostate cancer detection rate and is an important marker for diagnosis of cancer 
prostate. Serum PSA testing results in the increase in the number of patients 
localized prostate carcinoma and reduction in the advanced (metastatic) disease of 
cancer prostate. Serum PSA testing has resulted in downward stage migration of 
disease as well as early age at the time of diagnosis. 
Genetics and environmental factors contribute significantly in the 
development of the cancer prostate. Chronic inflammation may possibly play role 
in the development of cancer of the prostate gland. 
 Androgens and possibly estrogens contribute significantly in the 
pathogenesis of prostate cancer development. 
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 Prostate cancer risk is added to some extent by the presence of excess 
growth factors and possibly by dietary factors like saturated fat. 
HISTOLOGICAL VS CLINICAL CANCER:  
Controversies in the prostate cancer management occur in relation to several 
unique features of prostate. First, most prostate malignancy do not lead to serious 
morbidity or mortality.  
Autopsy studies and prevalence rate of prostate carcinoma in cysto prostatectomy 
specimens have shown about 30-46% of men aged 50 years and above have 
microscopic prostate cancer, but still less than 20% of men will develop clinical 
prostate malignancy in their lifetime. 
 Second, the natural history of prostate malignancy covers a wider spectrum 
of biologic activity unlike the natural history of most other malignancies (e.g. 
Lung, colon, breast or ovarian cancer) which behave aggressively and are 
uniformly fatal if left untreated.  
Some prostate cancers are small, well differentiated and unlikely to cause 
clinical disease while others are larger, poorly differentiated and more likely to 
undergo metastases and progress to death. 
 There are several hurdles in the optimal management of prostate cancer. An 
important challenge is related to screening, is to differentiate latent subclinical 
cancer from clinical prostatic carcinoma.  
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Majority of prostate cancers detected through an early detection program  
represent clinical rather than latent cancer and these group of patients are detected 
at an early stage of the disease. Prostate cancer screening in general population is 
controversial and based on the conclusions from two large randomized controlled 
trials, majority of the urological bodies report that currently mass screening for 
cancer prostate is not necessary. 
 Cancer prostate detection at an early period should be suggested for men   
who are willing to undertake the test after informed consent. The baseline prostatic 
specific antigen (PSA) estimation can be done at the age of 40 years and 
subsequent screening interval as per the baseline value. If the initial PSA value is  
≤ 1 ngm/ml patient may be screened of an interval of 8 years. For men older than 
75 years the test may not be that much essential as per some authors report. 
CLINICAL AND PATHOLOGICAL PRESENTATION: 
 Prostate cancer may present asymptomatic while detected by screening or 
early opportunistic detection program. Patient may present with symptoms and 
signs prostatism like hesitancy, poor-urinary stream, and increase frequency of 
micturition and rarely present with Hamaturia. prostate cancer patient may present 
with bladder outlet obstruction though Benign prostatic Hyperplasic (BPH) is most 
frequent etiology. 
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 Patient may present with Bladder diverticula, uremia due to distal ureteric 
obstruction, bone pain or pathological fractures due to bone metastasis. Patient 
may present with local hemorrhage due to necrosis of tumor or generalized 
bleeding due to liberation of large quantities of prostatic fibrinolysin, patient may 
present with hydroureteronephrosis either unilateral or bilateral. Urinary tract 
obstruction suggests an ominous prognosis. 
 Majority of prostate cancer begins in the peripheral zone and an adeno 
carcinoma being the most common (>95%) histology with variable degrees of 
differentiation. Cancer prostate may also arise from transition zone followed by 
central zone. 
 Transitional cell carcinoma, squamous cell carcinoma and rarely prostatic 
sarcoma may be found. Most prostatic adenocarcinoma develops from tubulo 
alveolar glands but the rare ductal prostatic cancers also can occur and have a poor 
prognosis. Poorly differentiated prostate cancers have more chance of having a 
pelvic lymph nodal involvement and poorer prognosis. 
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DIAGNOSIS: 
 Prostate Carcinoma is suspected because of an abnormality in digital rectal 
examination (DRE) or increase in serum PSA level. 
DIGITAL RECTAL EXAMINATION: 
 Most of cancer prostate are identified in the peripheral areas of the gland 
may be made out by digital rectal examination when tumour burden is about 0.2ml 
or more. Cancer prostate is detected by DRE abnormality alone in 18% of patient 
irrespective of PSA values. DRE abnormality in patient with a prostate specific 
antigen value of up to 2ngm/ml has positive prediction value for cancer in five to 
thirty percentages. Digital rectal examination variations is an important indication 
for taking prostatic biopsy as it is a predictor of more vigorous cancer prostate. 
Studies have shown that the PSA increase due to DRE is not clinically significant.                  
Prostate specific Antigen (PSA):  
 The diagnosis of cancer prostate has been revolutionized by the 
measurement of serum PSA level. PSA is produced almost exclusively by the 
prostatic epithelial cells and belongs to Kallikrein family.  Serum PSA levels may 
be increased in conditions like prostatitis, Benign prostatic hyperplasic (BPH), and 
also in other nonmalignant conditions apart from prostate cancer. The PSA level is 
an independent variable and better predictor of prostate carcinoma than abnormal 
findings in DRE or by Transrectal Ultra Sound (TRUS) examination. 
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 Several modifications of serum PSA level have been identified and 
described to improve the PSA specificity in the early and better detection of cancer 
prostate. These include PSA density, transition zone PSA density, Age-specific 
PSA reference range, and other PSA molecular forms. 
 In routine clinical evaluation these PSA derivatives and isoforms of PSA 
have very limited usefulness. 
 
Free/Total PSA ratio: 
 The ratio of free PSA to total prostate specific antigen is the current concept  
evaluated and  used in clinically to differentiate benign from cancer prostate. The 
ratio is useful for men with prostate specific antigen  levels between four and ten 
ngm/ml and a normal digital rectal examination. Prostate cancer risk is more than 
50% if the free total PSA ratio is <0.10 and prostate cancer risk falls to <10% if the 
ratio is >0.25. In addition the free to total PSA ratio is not useful if total PSA is 
>10ngm/ml and during follow-up cancer prostate patients. 
PSA Velocity (PSA-V): 
 PSA velocity is expressed in ngm/ml/year and is calculated as the increase in 
PSA per year. The increase in PSA of more than 0.75ngm/ml/year has got more 
risk of prostate cancer. 
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PSA Doubling Time: (PSADT) 
 It is defined as the time duration required for the patients PSA value to 
double in months or years. PSADT is useful in cancer prostate patients under 
surveillance for elevated PSA but negative prostatic biopsies, for active 
surveillance and for follow-up of rising PSA level post radical treatment. 
PSA Density: (PSAD) 
 PSA density is calculated as the serum PSA value per ml of prostatic tissue. 
Prostate volume can be measured by the following formula 
 Prostate volume = Length X height X width X 0.52 
 A PSAD value of  >0.15 ngm/ml of prostate gland has got more chance to lead to 
cancer prostate. 
TRANSRECTAL ULTRASONOGRAPHY (TRUS): 
 TRUS is very useful and mandatory for taking prostate needle biopsies. 
TRUS showing hypoechoic lesion in the peripheral zone of the prostate has better 
yield of cancer than isoechoic or hyperechoic areas.TRUS with help of colour 
Dopler study will be useful for better visualization of prostate cancer as shown in 
figure.3. 
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FIGURE 3. TRUS WITH COLOUR DOPPLER STUDY 
PATHOLOGY OF PROSTATE CANCER: 
 The Gleason grading in the more commonly used and widely accepted for 
prostate cancer. Gleason score is an independent prognostic factor for assessing the 
clinical behavior and treatment. It is based on the glandular architecture of the 
prostate tumour identified under low power magnification. A cytologic 
characteristic has got no role in the grading system. The architectural patterns 
includes the primary or predominant pattern and secondary or second more 
common pattern are identified and assigned a grade from one to five, with 5 being 
least differentiates and 1 being well differentiated. 
The various Gleason grades have been depicted in the following figure 4 to 8. 
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Figure 4.Gleason grade 1                       Figure 5. Gleason grade 2 
 
 
       
Figure 6.Gleason grade 3                             Figure 7.Gleason grade 4 
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                                                Figure 8. Gleason grade 5 
The prognosis of prostate cancer is based on the score obtained from sum of 
primary and secondary Gleason grades. 
 A tertiary Gleason grade of 4 or 5, if in excess of 5% of total prostate cancer 
volume indicates an unfavorable prognosis and predictor of biochemical 
recurrence. 
 Gleason scores range between 2 and 10.  
Studies have shown that the Gleason score can be improved by eliminating 
Gleason scores 4 or Lower for adenocarcinoma of prostate on TRUS guided needle 
biopsies.  
 The length in mm and percentage of cancer involvement per biopsy is best 
correlated with extra prostatic extension, tumour volume and prognosis following 
radical prostatectomy. Percentage of cancer involvement in biopsy and length of 
cancer involvement in mm are of equal prognostic value. 
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HISTOPATHOLOGY OF RADICAL PROSTATECTOMY SPECIMENS: 
 The objectives of histopathological examination of radical prostatectomy 
specimen are to obtain information about pathological stage, exact Gleason grade, 
and surgical margin status, location, extent of extra capsular extension or seminal 
vesical invasion & bladder neck involvement of the cancer prostate. Processing of 
prostatectomy specimen by total embedding technique is preferred. The presence 
of prostate cancer beyond confines of the prostate extra prostatic extension is in 
indicated by extra prostatic extension includes tumour involvement of periprostatic 
adipose tissue invasion of neuro vascular bundle or the anterior prostate and 
invasion of the bladder neck. 
 Surgical margin positivity is an important and definite risk factor for 
postoperative  recurrence. Margin status is taken as positive if tumour cells are in 
contact with inked surface and negative when tumour cells are away from inked 
surface or close to inked surface. 
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STAGING OF CANCER PROSTATE BY CLINICAL ASSESSMENT: 
 The initial workup of cancer prostate patient is done by digital rectal 
examination, serum prostate specific antigen measurement and extension of 
assessment made by bone scan with supplementation by CT scan or MRI and chest 
x-ray as required. 
T  STAGING: 
Local tumour stage is done by T Staging where the difference between  
intracapsular (T1-T2) and extra prostatic involvement (T3-T4) has more important 
impact on treatment decisions and patient outcomes. 
DRE often underestimates the prostate cancer involvement and positive 
predictive value of DRE and pathological tumour stage was <50%. Serum PSA 
values increases as the age advances and it has got limited potential to predict the 
ultimate pathological stage. Serum PSA, Gleason biopsy score and clinical T stage 
have been proved to be more useful in assessing the final pathological  stage of the 
cancer prostate.  
TRUS not accurately stage the disease and hence currently TRUS is not used 
for local tumour (T) staging and is done with either CECT or MRI of Abdomen 
and Pelvis may predict the local staging and also assess the neurovascular bundle 
involvement. 
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Nodal Staging: 
  Nodal staging should be done only when the nodal involvement alters 
the management option. Nodal staging is routinely done when curative or 
definitive treatment is planned. High risk of nodal metastasis is predicted by the 
following factors high serum PSA levels, Stage T2B & T3 tumour, poorly 
differentiated tumour and presence of perineural invasion current literature suggest 
that pelvic nodal metastasis is better staged with CT or MRI although CT Scan is 
marginally superior to MRI. Lymph nodal metastasis is considered when the 
Lymph nodal size of 0.8cm for round nodes and around one cm in short axis for 
oval lymph nodes and was rated in either CT or MRI. Patients with PSA 
<20ngm/ml, Gleason Score of ≤ 6 and ≤stage T2 have got a <10% glance having 
nodal disease and can be spared from nodal evaluation. 
 Pelvic Lymph nodal dissection provides the optimal staging in patients with 
clinically localized cancer prostate. 
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Metastasis: 
 Majority of cancer prostate patients die from axial skeleton metastasis. The 
prognosis of patients with cancer prostate is predicted by the presence and extent 
of bone metastasis, measurement of alkaline phosphates (skeletal) and serum PSA 
at the same time better predicts clinical outcomes. 
 Most sensitive method of assessing bone metastasis is by bone scintigraphy 
and is superior to skeletal survey, clinical examination & measurement of serum 
alkaline phosphates. 
 The current radiopharmaceuticals available for better evaluation of bone 
metastasis is technetium diphosphonates because of better bone to soft tissue 
uptake. 
 Prostate cancer spread mainly to bone and is followed by lymph nodal areas, 
Lungs, Liver, central nervous system & Skin.  
 Serum PSA is currently maker of choice for predicting the metastasis in 
cancer prostate patients. Current indications for bone scan in asymptomatic cancer 
prostate patients include serum PSA>20ngm/ml, Gleason Score ≥8, clinical stage 
T3 & T4.  
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MANAGEMENT: 
RADICAL PROSTATECTOMY: 
 At present, radical prostatectomy is the recommended treatment option for 
patient with localized cancer prostate with better overall survival time and cancer 
specific survival period compared with conservative treatment. 
 Radical prostatectomy involves excision of whole prostate tissue between 
the bladder and urethra, and removal of both seminal vesicles along with adequate 
tissue all around to obtain negative tumour at the  margins, along with bilateral 
pelvic lymph nodal dissection. In cancer prostate patient with localized disease and 
a life expectancy of ≥ 10 years is to achieve disease eradication, preservation of 
urinary continence and erectile function. 
 Life expectancy is atmost importance in counseling for radical 
prostatectomy in a prostate cancer patients. No patients should be denied of 
curative radical prostatectomy merely based on chronological age . 
 Radical Prostatectomy is carried out by open approach either by retropubic 
method or by perineal and recently minimally invasive methods like robot assisted 
laparoscopic Prostatectomy (RALP) and Laparoscopic Radical Prostatectomy 
(LRP) are progressing rapidly. 
 Radical Prostatectomy is currently recommended for patients with T1c 
tumours, T2a and also in patient with intermediate risk group like T2B-T2C, Gleason 
score > with PSA 10-20ngm/ml group.  
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Radical Prostatectomy is controversial in high risk localized disease with CT3A or 
Gleason score 8-10 & Serum PSA >20ngm/ml and is reasonable option only in 
selected patients with low volume prostate cancer. 
HORMONAL THERAPY: 
 Hormonal injection of cancer prostate was started for the management of 
metastatic disease seven decades ago (Huggins & Hodges) and since then it is used 
in the management of advanced prostate cancer. Currently androgen suppression 
treatment is extended in the management of non-metastatic prostate cancer, in 
younger patient and in recurrent cancer prostate after definitive management. 
 Androgens are basically responsible for the stimulation of prostate cellular 
development, function and proliferation.  Testosterone  is critical for the growth & 
alteration of prostate cancer cells. Testes are the major androgen sources followed 
by adrenal androgen which occurs for 5-10% of androgens.  
 Testosterone is under the control of hypothalamo pituitary gonadal axis. 
Anterior pituitary gland is stimulated by Luteinizing hormone releasing hormone 
and in turn results in the release of Luteinizing hormone (LH) and follicle 
stimulating hormone (FSH). LH activates testicular leydig cells to release 
testosterone inside the prostate cells 5 & dihydroxy testosterone are produced from 
testosterone by the action of (DHT) 5alpha reductase enzyme. DHT is more potent 
(10 times) than serum testosterone. 
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 Testosterone in circulation is aromatized peripherally and metabolized to 
estrogens, which along with androgen exert a negative bio feedback action over 
hypothalamus. 
 Prostate cells undergo programmed cell death (apoptosis) if they are 
deprived of androgen stimulation effects. Currently androgen suppression therapy 
is widely used in the management advanced prostate cancer. 
Mechanisms of Lowering Serum Testosterone: 
 
Castration Level: 
 
 Surgical castration is considered the mainstay of androgen deprivation 
therapy against which other treatment options are compared. The standard castrate 
range is <50ngm/ml and few studies says it may be <20ngm/ml. 
B/L Orchiectomy (Surgical Castration): 
 B/L orchiectomy either subcapsular or total is a simple, standard treatment 
option with negligible complication rate. It is usually preformed under local 
anaesthesia and a faster way attain a castration level within 12-24 hours. The 
disadvantage of surgical castration is it is irreversible and it exerts negative 
psychological effect on manhood. 
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Oestrogens: 
 Oestrogens exerts is hormonal effects by several mechanism like androgen 
inactivation, decrease in the  LHRH secretion, control of Leydig cell function by 
direct action and cytotoxic action to the prostate epithelium (directly). 
Diethyl stilboesterol (DES): 
 The commonly used oestrogen in cancer prostate the hormonal effects of 
DES are comparable to that of surgical castration. The cardiovascular adverse 
effect makes this drug less practiced than surgical castration. 
LHRH agonist: 
 Currently LHRH agonist have been used widely in the management of 
advanced cancer prostate as an alternate to surgical castration. LHRH analogues 
are generally administered as depot injections on a monthly basis, or once in two to 
three months and occasionally twice a year basis. After an in initial injection they 
produce testosterone surge or LH “flare up” event which usually starts within 2-3 
days and persists for about 7-10 days. The main disadvantage of LHRH agonist 
induced flare phenomenon results in worsening of bone pain, bladder outlet 
obstruction, spinal cord compression effect, and fatal cardiovascular effects 
because of hyper coagulation state. Simultaneous treatment with an anti androgen 
medication reduces the occurrence of clinical flare up response but still will not 
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totally suppress the flare risk. Anti androgen treatment should be initiated on the 
same day and continued for a minimum of 2 week period. 
LHRH antagonists: 
 LHRH receptors are completely blocked by LHRH antagonist with an 
immediate effect which results in sudden fall in LH, FSH and serum testosterone 
values without LH flare events. This mechanism of action is more useful in 
avoiding flare response in advanced disease. The major drawback of LHRH 
antagonist is life threatening anaphylaxis due to histamine release. New generation 
LHRH antagonist may be occasionally useful to control flare-up with LHRH 
monotherapy in few symptomatic metastatic patients. 
ANTIANDROGENS: 
 Two major classes of antiandrogens are namely steroidal and non-steroidal 
groups. 
Cyproterone acetate: 
 First antiandrogen used and most commonly used drug in the past with  half 
life of around 30-40 hours and  administered orally 100mg each in twice or thrice 
daily dosing schedule. 
 
 
 28 
NON STEROIDAL ANTI-ANDROGENS: 
 Non-steroidal antiandrogen when used as monotherapy compared with 
surgical castration has improved quality of life and better compliance. This group 
of drugs does not block the secretion of testosterone and maintains libido, Bone 
mineral density and Physical performance status. The common side effects 
includes liver toxicity, hot flashes, gynaecomastia and breast pain. Bicalutamide 
have shown better safety and tolerance than other drugs in this group. 
COMBINED ANDROGEN BLOCKAGE: 
 Although surgical castration results in >95% reduction in serum testosterone 
levels, adrenal androgen secretion results in production of DHT in the prostate 
cells and results in continued androgen serum for the prostate cells. The adrenal 
sources of androgens can be completely controlled  by adding an anti-androgen to 
either medical or surgical androgen suppression resulting in complete (total or 
maximal) androgen blockage (CAB) CAB offers small survival advantage <5% at 
the expense of increased cost and more side effects. 
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LOW SERUM TESTOSTERONE AND PROSTATE CANCER: 
 As the age advances serum testosterone level and cancer prostate incidence 
is on the higher side. Various studies have conducted and reported contrasting 
results with regards to serum testosterone level and cancer prostate risk.
 Patients with low serum testosterone may present with clinical symptoms of 
loss of libido, depression and diminished bone mineral density and such condition 
is defined as hypogonadism.  
Various studies related to cancer prostate and serum testosterone were 
analyzed by the endocrine and prostate cancer collaborative group and reported 
that there was no well defined association between cancer prostate and serum 
levels of testosterone, androstenediane, dihydrotestosterone (DHT) and estradiol 
levels. Older men with increased risk of cancer prostate had an association with 
low serum testosterone.  
Few investigations have reported prostate cancer patients with low serum 
testosterone had worse prognosis and higher Gleason grade to metastatic cancer 
prostate compared with normal serum testosterone. Hence the purpose our present 
study is to find out the actual association between cancer prostate patients and low 
normal serum testosterone patients.Further studies are warranted to confirm the 
relationship. 
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MATERIALS AND METHODS 
 
TITLE OF THE STUDY 
 
A study of association of low serum testosterone and prostate cancer behaviour 
  
PERIOD OF STUDY  
 
March 2013 – February 2014 
  
STUDY DESIGN  
 
This study is a prospective study of analyzing the association of low serum 
testosterone and prostate cancer behaviour with patients with normal testosterone. 
 
PLACE OF STUDY  
 
The study was conducted in the Department of Urology, Madras Medical College 
and Rajiv Gandhi Government Hospital, Chennai- 3  
 
ETHICAL CLEARANCE  
The institutional ethical review board at our hospital approved the study.  
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Inclusion criteria 
All newly diagnosed prostate cancer (TRUS guided biopsy proven ) patients with  
age more than 40 years  in our institution were enrolled . 
Exclusion Criteria: 
• Patients already  on testosterone replacement therapy 
• Patients on other hormonal therapy 
• Men taking medications known to lower serum PSA level (Finasteride or 
Dutasteride)  
Method of Study 
 Informed consent was obtained from all patients. All TRUS biopsy proven cancer 
prostate patients were enrolled to a maximum number of 100. All details were 
recorded as per the proforma (Appendix-3). Blood investigations like serum PSA, 
serum testosterone and other baseline investigations were obtained. The serum 
determinations of Testosterone obtained between 7 – 9.30 am. The serum 
Testosterone levels measured by appropriate standard protocols.  
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Patients were divided into two groups based on the serum testosterone 
levels. Patients with low serum testosterone levels (< 250 ng/dl ) were categorized 
as Group A  and  patients with normal  serum testosterone levels ( > 250 ng/dl ) 
were categorized as Group B and and the findings between two groups will be 
compared.  
Clinical staging was done for all patients based on the findings in bone scan, 
Contrast enhanced CT Scan or MRI Scan of abdomen and pelvis. Surgery was 
done and all patients were followed up after one month of surgery. 
All  prostate cancer patients who were enrolled in this study were assessed at 
the time of admission based on detailed  clinical examination,  complete baseline 
blood investigations ,Serum PSA, Serum testosterone ,Gleason grading (TRUS 
biopsy) which includes primary ,secondary and total Gleason score or sum , 
Imaging studies ( bone scan, CECT/MRI abdomen and pelvis and chest  x-ray ). 
Patients with localized prostate cancers which include patients with Clinical 
stage T1 & T2 without regional pelvic nodal involvement and metastasis were 
counseled and given the option of radical prostatectomy (RP) and other patients 
who were in advanced stage of the disease which include clinical T3 and T4 
disease  and metastatic prostate cancer  were managed with hormonal therapy in 
the form of  surgical castration followed by anti-androgen therapy. 
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Patients who underwent radical prostatectomy (RP) were followed up post 
operatively with histopathological specimen analysis  and parameters like  post 
operative Gleason grade , pathological tumour (PT) status, pathological node (PN) 
status, surgical margin status (SMS), extra capsular extension (ECE) of tumour and 
seminal Vesical invasion (SVI)  were compared between the prostate cancer 
patients with low serum testosterone (group A) and normal testosterone ( group B).  
Statistical analysis 
The patient age and serum PSA were compared with the help of Student's t-test in 
the low- and normal serum testosterone groups. Chi-square test (Pearson’s) was 
applied to compare the prostate cancer parameters between low and normal serum 
testosterone patients. Statistical analyses were done using software SPSS version 
17.0.  A p value equal to or below 0.05 was taken as statistically significant. 
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OBSERVATION AND RESULTS 
Total of 106 patients with cancer prostate were taken into our study of which 5 
patients on 5 alpha reductase inhibitors and 1 patient on testosterone replacement 
therapy were excluded from our study and finally 100 patients were enrolled in our 
study of which patients with low testosterone level (<250 ng/dl ) were categorized 
as group A  and the  remaining  patients with normal testosterone level 
 (> 250 ng/dl) were categorized as group B. The patient demographics between the 
two groups are presented in the following figure.1. 
 
 
 
 
 
Figure.1 
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The patient demographics between the two groups are presented in the following 
table 1. 
 
Age in years * Serum Testosterone 
 
   Serum Testosterone Total 
P value 
    < 250 > 250   
 
Age in years 40-50 Count 1 6 7  
    % within Age 
in years 
14.3% 85.7% 100.0% 
 
    % within 
Serum 
Testosterone 
4.3% 7.8% 7.0% 
 
  51-60 Count 9 18 27  
    % within Age 
in years 
33.3% 66.7% 100.0% 
 
    % within 
Serum 
Testosterone 
39.1% 23.4% 27.0% 
 
  61-70 Count 9 38 47 .669 
    % within Age 
in years 
19.1% 80.9% 100.0% 
 
    % within 
Serum 
Testosterone 
39.1% 49.4% 47.0% 
 
  71-80 Count 3 11 14  
    % within Age 
in years 
21.4% 78.6% 100.0% 
 
    % within 
Serum 
Testosterone 
13.0% 14.3% 14.0% 
 
  > 80 Count 1 4 5  
    % within Age 
in years 
20.0% 80.0% 100.0% 
 
    % within 
Serum 
Testosterone 
4.3% 5.2% 5.0% 
 
Total Count 23 77 100  
  % within Age 
in years 
23.0% 77.0% 100.0% 
 
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
 
 
   
 
 
Table 1 
 
The prostate cancer patients population demographics shown in above table 1.and 
is found not statistically significant between the two groups .The youngest age of 
the patient was 45 years and oldest recorded age was 85 years. 
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Serum PSA * Serum Testosterone 
The serum PSA levels were measured in all our study patients and the PSA levels 
between patients with group A and group B were analyzed and the results were 
depicted below in table 2. The majority (74%)of patients in low testosterone group 
has got a serum PSA of more than 20 values compared  with only 34% of patients 
in the corresponding group. P value is found to be statistically significant.  
   Serum Testosterone Total P value 
    < 250 > 250    
Serum PSA < 10 Count 1 16 17  
    % within 
Serum PSA 
5.9% 94.1% 100.0% 
 
    % within 
Serum 
Testosteron
e 
4.3% 20.8% 17.0% 
 
  10-20 Count 5 35 40  
    % within 
Serum PSA 
12.5% 87.5% 100.0% 
 
    % within 
Serum 
Testosteron
e 
21.7% 45.5% 40.0% 
.003 
  > 20 Count 17 26 43  
    % within 
Serum PSA 
39.5% 60.5% 100.0% 
 
    % within 
Serum 
Testosteron
e 
73.9% 33.8% 43.0% 
 
Total Count 23 77 100  
  % within 
Serum PSA 
23.0% 77.0% 100.0% 
 
  % within 
Serum 
Testosteron
e 
100.0% 100.0% 100.0% 
 
 
        Table 2 
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TGS * Serum Testosterone 
The comparison between patients total Gleason score ( low  <7,intermediate 7 and 
high 8-10 ) is shown in table.3 between two groups. Most of the patients (82.6%) 
in low testosterone group had a higher Gleason grade (8-10) compared to the 
normal testosterone group. 
 P value is found statistically significant (<005 ). 
 
   Serum Testosterone Total 
P value 
    < 250 > 250   
 
TGS < 7 Count 
0 34 34 
 
    % within TGS 
.0% 100.0% 100.0% 
 
    % within 
Serum 
Testosterone 
.0% 44.2% 34.0% 
 
  7 Count 
4 39 43 
 
    % within TGS 
9.3% 90.7% 100.0% 
 
    % within 
Serum 
Testosterone 
17.4% 50.6% 43.0% 
 
  8-10 Count 
19 4 23 
<.005 
    % within TGS 
82.6% 17.4% 100.0% 
 
    % within 
Serum 
Testosterone 
82.6% 5.2% 23.0% 
 
Total Count 
23 77 100 
 
  % within TGS 
23.0% 77.0% 100.0% 
 
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
     Table 3. 
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TGS * Serum Testosterone 
 
The relation between total Gleason score (TGS) and prostate cancer patients serum 
testosterone levels between the two groups is shown in figure 2, as below.patients 
in low testosterone group had higher proportion of high gleason score compared to 
the normal testosterone group. 
 
 
     Figure 2 
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Clinical Stage - T * Serum Testosterone 
 
The preoperative clinical tumour (T) status, Nodal status (N), and metastasis (M) 
status were analyzed   and the results between the two groups were represented in 
table 4 as below .patients in low testosterone group had higher overall tumour 
stage, higher nodal stage and extensive metastases on clinical evaluation compared 
to the normal testosterone group. P value is found statistically significant. 
   Serum Testosterone Total 
P value 
    < 250 > 250   
 
Clinical Stage - T T2A Count 1 7 8  
    % within Clinical 
Stage - T 
12.5% 87.5% 100.0% 
 
    % within Serum 
Testosterone 4.3% 9.1% 8.0% 
 
  T2B Count 6 10 16  
    % within Clinical 
Stage - T 
37.5% 62.5% 100.0% 
 
    % within Serum 
Testosterone 26.1% 13.0% 16.0% 
 
  T2C Count 2 3 5  
    % within Clinical 
Stage - T 
40.0% 60.0% 100.0% 
 
    % within Serum 
Testosterone 8.7% 3.9% 5.0% 
 
  T3A Count 2 26 28  
    % within Clinical 
Stage - T 
7.1% 92.9% 100.0% .002 
    % within Serum 
Testosterone 8.7% 33.8% 28.0% 
 
  T3B Count 8 31 39  
    % within Clinical 
Stage - T 
20.5% 79.5% 100.0% 
 
    % within Serum 
Testosterone 34.8% 40.3% 39.0% 
 
  T4A Count 2 0 2  
    % within Clinical 
Stage - T 
100.0% .0% 100.0% 
 
    % within Serum 
Testosterone 8.7% .0% 2.0% 
 
  T4B Count 2 0 2  
    % within Clinical 
Stage - T 
100.0% .0% 100.0% 
 
    % within Serum 
Testosterone 8.7% .0% 2.0% 
 
Total Count 23 77 100  
  % within Clinical 
Stage - T 
23.0% 77.0% 100.0% 
 
  % within Serum 
Testosterone 100.0% 100.0% 100.0% 
 
 
     Table 4. 
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Clinical Stage - T * Serum Testosterone 
  
Clinical tumour (T) status,Nodal status (N) were analyzed   and the results between 
the two groups were represented in figure 3, as below. 
 
      Figure 3 
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Clinical Stage - N * Serum Testosterone 
Patients clinical Nodal status (N) were analyzed   and the results between the two 
groups were represented in table 5,as below.group 1 patients had a higher nodal 
involvement than group 2 patients. P value is found statistically significant. 
   Serum Testosterone Total P value 
    < 250 > 250    
Clinical Stage - 
N 
N0 Count 
7 68 75 
 
    % within 
Clinical Stage – 
N 
9.3% 90.7% 100.0% 
 
    % within Serum 
Testosterone 
30.4% 88.3% 75.0% 
 
  N1 Count 16 9 25  
    % within 
Clinical Stage – 
N 
64.0% 36.0% 100.0% 
<0.05 
    % within Serum 
Testosterone 
69.6% 11.7% 25.0% 
 
Total Count 23 77 100  
  % within 
Clinical Stage – 
N 
23.0% 77.0% 100.0% 
 
  % within Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
Table 5. 
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Clinical Stage - N * Serum Testosterone 
Patients with low serum testosterone group had more proportion of people with 
nodal metastasis (N 1 group ) than the normal testosterone group as shown in 
figure 4. 
 
     Figure 4. 
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Clinical Stage - M * Serum Testosterone 
 
Patients clinical metastasis status (M) were analyzed   and the results between the 
two groups were represented in table 6, as below. P value is found statistically 
significant. 
 
   Serum Testosterone Total 
P value 
    < 250 > 250   
 
Clinical Stage - 
M 
M0 Count 
9 64 73 
 
    % within 
Clinical Stage – 
M 
12.3% 87.7% 100.0% 
 
    % within Serum 
Testosterone 39.1% 83.1% 73.0% 
 
  M1A Count 0 1 1  
    % within 
Clinical Stage – 
M 
.0% 100.0% 100.0% 
 
    % within Serum 
Testosterone .0% 1.3% 1.0% 
 
  M1B Count 11 12 23  
    % within 
Clinical Stage – 
M 
47.8% 52.2% 100.0% 
<.005 
    % within Serum 
Testosterone 47.8% 15.6% 23.0% 
 
  M1C Count 3 0 3  
    % within 
Clinical Stage – 
M 
100.0% .0% 100.0% 
 
    % within Serum 
Testosterone 13.0% .0% 3.0% 
 
Total Count 23 77 100  
  % within 
Clinical Stage – 
M 
23.0% 77.0% 100.0% 
 
  % within Serum 
Testosterone 100.0% 100.0% 100.0% 
 
 
      Table 6. 
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Management * Serum Testosterone 
 
The patient management options between the low testosterone group and normal 
testosterone group were analyzed in the table 7 as shown below. 
 
 
   Serum Testosterone Total P value 
    < 250 > 250    
Management RP Count 5 6 11  
    % within 
Management 
45.5% 54.5% 100.0%  
    % within 
Serum 
Testosterone 
21.7% 7.8% 11.0% 
 
  Hormonal Count 18 71 89  
    % within 
Management 
20.2% 79.8% 100.0% 
.061 
    % within 
Serum 
Testosterone 
78.3% 92.2% 89.0% 
 
Total Count 23 77 100  
  % within 
Management 
23.0% 77.0% 100.0%  
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
Table 7. 
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Management * Serum Testosterone 
 
Management of patients in low serum testosterone and normal testosterone level 
were analyzed in following figure 5. 
 
 
 
    Figure 5 
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Pathological stage - PT * Serum Testosterone 
 
The pathological tumour characteristics were compared between the two groups and 
was represented in the following table 8.Although overall pathological T staging is 
not statistically significant the patients in low testosterone group had higher T 3 
disease than group B patients. Overall   P value is not statistically Significant. 
 
   Serum Testosterone Total P value 
    < 250 > 250    
Pathological 
stage – PT 
PT2A Count 
1 4 5 
 
    % within 
Pathological 
stage - PT 
20.0% 80.0% 100.0% 
 
    % within Serum 
Testosterone 20.0% 66.7% 45.5% 
 
  PT3A Count 1 1 2  
    % within 
Pathological 
stage - PT 
50.0% 50.0% 100.0% 
 
    % within Serum 
Testosterone 20.0% 16.7% 18.2% 
 
  PT3B Count 3 0 3  
    % within 
Pathological 
stage - PT 
100.0% .0% 100.0% 
.124 
    % within Serum 
Testosterone 60.0% .0% 27.3% 
 
  PT2B Count 0 1 1  
    % within 
Pathological 
stage - PT 
.0% 100.0% 100.0% 
 
    % within Serum 
Testosterone .0% 16.7% 9.1% 
 
Total Count 5 6 11  
  % within 
Pathological 
stage - PT 
45.5% 54.5% 100.0% 
 
  % within Serum 
Testosterone 100.0% 100.0% 100.0% 
 
 
      Table 8. 
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Pathological stage - PN * Serum Testosterone 
 
Post operative pathological nodal status between the two groups were compared as 
shown below in table 9. Patients in low testosterone group had more proportion of 
pathological lymph nodal involvement than patients in normal testosterone group. 
P value was found to be statistically significant ( p = .015) 
 
 
   Serum Testosterone Total 
P value 
    < 250 > 250   
 
Pathological 
stage – PN 
PN0 Count 
1 6 7 
 
    % within 
Pathological 
stage - PN 
14.3% 85.7% 100.0% 
 
    % within 
Serum 
Testosterone 
20.0% 100.0% 63.6% 
 
  PN1 Count 
4 0 4 
 
    % within 
Pathological 
stage - PN 
100.0% .0% 100.0% 
.015 
    % within 
Serum 
Testosterone 
80.0% .0% 36.4% 
 
Total Count 
5 6 11 
 
  % within 
Pathological 
stage – PN 
45.5% 54.5% 100.0% 
 
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
 
      Table 9. 
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Post operative Gleason Grade * Serum Testosterone 
 
Post  prostatectomy histopathological specimen total Gleason score between the 
two groups were analyzed and shown in table 10, as below. P value was found 
statistically significant. 
 
   Serum Testosterone Total P value 
    < 250 > 250    
Grade 7 Count 0 4 4  
    % within 
Grade 
.0% 100.0% 100.0% 
 
    % within 
Serum 
Testosterone 
.0% 66.7% 36.4% 
 
  8-10 Count 5 2 7  
    % within 
Grade 
71.4% 28.6% 100.0% 
.022 
    % within 
Serum 
Testosterone 
100.0% 33.3% 63.6% 
 
Total Count 5 6 11  
  % within 
Grade 
45.5% 54.5% 100.0% 
 
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
Table 10 
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Post operative Gleason Grade * Serum Testosterone 
 
Post  prostatectomy histopathological specimen total Gleason score between the 
two groups were analyzed and shown in the following figure 6 . P value was found 
statistically significant. 
 
 
              Figure 6. 
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SMS * Serum Testosterone 
Post radical prostatectomy histopathological specimen Surgical Margin 
Status (SMS) between the two groups were analyzed and shown in table 11, as 
below. Most ( > 60%) of the patients in low serum testosterone group had positive 
surgical margin when compared to none in normal testosterone group. P value was 
found statistically significant (P = .026 )  
 
 
   Serum Testosterone Total 
P value 
    < 250 > 250    
SMS Positive Count 3 0 3  
    % within 
SMS 
100.0% .0% 100.0%  
    % within 
Serum 
Testosterone 
60.0% .0% 27.3% 
 
  Negative Count 2 6 8  
    % within 
SMS 
25.0% 75.0% 100.0% 
.026 
    % within 
Serum 
Testosterone 
40.0% 100.0% 72.7% 
 
Total Count 5 6 11  
  % within 
SMS 
45.5% 54.5% 100.0%  
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
      Table 11. 
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SMS * Serum Testosterone 
The surgical margin status between the low and normal serum testosterone group 
were analyzed in the following figure 7. 
      
 
 
 
   Figure 7 
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ECE * Serum Testosterone 
 
Post prostatectomy histopathological specimen Extra Capsular Extension (ECE ) 
status between the two groups were analyzed and shown in table 12,Patients with 
low serum testosterone group had more number of extra capsular extension than 
normal serum testosterone group as  shown below. P value was found statistically 
significant.  
P value = 0.036 
 
 
   Serum Testosterone Total P value 
    < 250 > 250    
ECE Positive Count 4 1 5  
    % within 
ECE 
80.0% 20.0% 100.0% 
 
    % within 
Serum 
Testosterone 
80.0% 16.7% 45.5% 
 
  Negative Count 1 5 6  
    % within 
ECE 
16.7% 83.3% 100.0% 
.036 
    % within 
Serum 
Testosterone 
20.0% 83.3% 54.5% 
 
Total Count 5 6 11  
  % within 
ECE 
45.5% 54.5% 100.0% 
 
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
Table 12. 
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ECE * Serum Testosterone 
 
Post prostatectomy histopathological specimen Extra Capsular Extension (ECE ) 
status between the two groups were analyzed in the following figure 8 and patients 
in low serum testosterone group had higher positive surgical margin when 
compared to the normal testosterone group. 
 
 
    Figure 8. 
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SVI * Serum Testosterone 
Post  prostatectomy histopathological specimen Seminal Vesical Invasion (SVI ) 
status between the two groups were analyzed and were shown in the table 13, as 
below.the post operative seminal Vesical invasion was more in low serum 
testosterone group than in normal serum testosterone group. P value was found 
statistically significant . 
 
P value = .026  
 
 
   Serum Testosterone Total P value 
    < 250 > 250    
SVI Positive Count 3 0 3  
    % within SVI 100.0% .0% 100.0%  
    % within 
Serum 
Testosterone 
60.0% .0% 27.3% 
 
  Negative Count 2 6 8  
    % within SVI 25.0% 75.0% 100.0% .026 
    % within 
Serum 
Testosterone 
40.0% 100.0% 72.7% 
 
Total Count 5 6 11  
  % within SVI 45.5% 54.5% 100.0%  
  % within 
Serum 
Testosterone 
100.0% 100.0% 100.0% 
 
 
 
     Table 13. 
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SVI * Serum Testosterone 
Post  prostatectomy histopathological specimen Seminal Vesical Invasion (SVI ) 
status between the two groups were analyzed and were depicted in figure 9, as 
below.the patients in group A had more seminal Vesical invasion when compared  
With normal serum testosterone group. 
 
 
    Figure 9. 
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DISCUSSION 
  The view that Serum testosterone has got a crucial part in the development 
of cancer prostate is controversial and widely discussed    and various studies have 
analyzed and documented the association between low level of serum testosterone 
and metastatic disease and high grade cancer prostate. 
 Morgentaler et al. have shown a higher incidence of cancer prostate in 
patients with low serum testosterone. Other studies by Massachusetts aging study 
have reported no association between androgens including serum testosterone and 
cancer prostate risk. 
Some of the previous  studies have stated concerns  about the inceased risk 
of  prostate cancer  in men with lower levels  of testosterone . In patients with  
hypogonadal clinical status and  with  a PSA < 4.0 ng/ml, TRUS guided prostate 
biopsy has shown cancer in aruond  15%, with risk of the cancer increases twice 
when met with greater reduction in the serum testosterone levels. 
        The association between serum testosterone and cancer prostate is not yet well 
established. The possible explanation for the link between low serum testosterone 
and cancer prostate is due to the negative feedback effect of serum testosterone on 
hypothalamo pituitary axis. Miller et al. have shown that cancer prostate inhibits 
serum testosterone production by the hormone inhibin. 
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The association between low serum testosterone level and high-risk cancer 
prostate may be due to chronic disease induced hormonal change.   
In our present study , patients with low serum testosterone and its 
association with TRUS biopsy Gleason grade, serum PSA, Clinical Tumour (T) 
status, Clinical nodal (N) status, Clinical metastasis(M) status ,Pathological tumour 
(PT) and Pathological nodal (PN) status, postoperative histo-pathological  
specimens Gleason total score ,Surgical margins status, extra capsular extension  
and Seminal vesical invasion were analyzed in comparison with normal serum 
testosterone patients. 
The association between low level of serum testosterone and high Gleason 
grade prostate cancer have been demonstrated by Zhang et al. 
In our study greater percentage of patients with low serum total testosterone 
were presented with high Gleason total scores ( ≥ 8).  
  Our study report was supported by similar to the study by Schatzl et al have 
shown that patients with low level of serum testosterone were found to have higher 
Gleason total score when plotted against normal serum testosterone. 
Our study also shown that patients with low total testosterone level were 
associated with  advanced clinical stage of the disease including clinical tumour 
status, nodal status and metastasis to bone and other viscera compared to patients 
with normal level of serum testosterone. 
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The results of our study were similar to previous study done by perez 
Marquez et al. who found that patients with low testosterone levels are at an 
increased risk of metastatic disease and higher risk of tumour progression. 
The study by Hoffman et al. reported that patients with low serum 
testosterone is a marker of aggressive nature of cancer prostate. 
 
Another study also shown that serum testosterone values are an important 
and independent  marker in assessing  prostate biopsy positivity. 
The post prostatectomy histo-pathological specimens Gleason score, 
pathological tumour stage and baseline serum PSA are associated with an 
increased risk of aggressive prostate cancer. 
 
In our study patients with low serum total testosterone were associated with 
higher Gleason score and less favorable pathological stage and an increased 
incidence of positive surgical margins in the resected specimen, extra capsular 
extension of tumour either unilateral or bilateral and finally positive Seminal 
Vesical invasion . 
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There are few limitations in our study which has to be taken care in future 
prospective studies of similar population groups. One of the limitation is small 
prostate cancer population size and again the number of patients who presented 
with low serum levels of testosterone were only 23. Second limitation of our 
present study is number of patients who were fit under the criteria for radical 
prostatectomy was only 11.Finally the follow up period up is short and it is 
recommended that in the future long duration studies involving larger group of 
patients will be helpful in confirming our current study report and also through 
more light on this ever debated prostate cancer study. 
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CONCLUSION 
 
Low total serum testosterone is associated with higher proportion of 
predominant Gleason pattern 4, an indicator of aggressive prostate cancer. 
Patients with low serum testosterone levels were associated with an 
increased serum PSA levels compared with patients in normal serum testosterone 
levels.  
Patients with low testosterone who were managed by radical prostatectomy 
had a higher proportion of positive surgical margin, extra capsular extension and 
seminal Vesical invasion suggesting an aggressive prostate cancer behaviour. 
Preoperative total testosterone should be routinely added to serum prostate 
specific antigen estimation to improve prostate cancer management. 
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INFORMED CONSENT FORM 
         
 
Title of the study:  
  
“A study of association of low serum testosterone and prostate cancer 
behaviour” 
 
Name of the Participant:  
 
Name of the Principal Investigator :  Dr.K.ARUNPRASAD 
 
Name of the Institution : Rajiv Gandhi Govt. General Hospital, Chennai -3. 
 
Documentation of the informed consent 
 
I _____________________________ have read the information in this form (or it 
has been read to me). I was free to ask any questions and they have been answered. 
I am over 18 years of age and, exercising my free power of choice, hereby give my 
consent to be included as a participant in “A study of association of low serum 
testosterone and prostate cancer behaviour” 
 
1. I have read and understood this consent form and the information provided to 
me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have 
taken in the past 3 months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this 
study. 
7. I agree to cooperate with the investigator and I will inform him/her immediately 
if I suffer unusual symptoms. 
8. I have not participated in any research study within the past 6 month(s) 
10. I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital.  
11. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the  regulatory 
authorities, Govt. agencies, and IEC. I understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are 
publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given in this 
document has been clearly explained to me and understood by me, I will be given a 
copy of this consent document. 
 
 
For adult participants: 
 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
 
Name _________________________ Signature_________________  
 
Date________________ 
 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
 
 
 
Address and contact number of the impartial witness: 
_________________________________ 
Name and Signature of the investigator or his representative obtaining consent: 
Name _________________________ Signature_________________ 
Date________________ 
                                    
MuhŒ¢á x¥òjš foj« 
R¡»a (¥uhÞnl£) Ru¥ã ò‰WnehÆ‰F« Fiwªj msî 
blÞnlhÞonuh‹ Ru¥ã ÚU¡F« cŸs bjhl®ig  
f©l¿í« MuhŒ¢á  
bga®  :     njâ    : 
taJ  :     cŸ / òw nehahË v© : 
ghš  :     MuhŒ¢á nr®¡if v© : 
ïªj MuhŒ¢á‹ Étu§fS« mj‹ neh¡f§fS« KGikahf 
vd¡F bjËthf És¡f¥g£lJ. 
vd¡F És¡f¥g£l Éõa§fis eh‹ òÇªJbfh©L vdJ 
r«kj¤ij bjÇÉ¡»nw‹. 
R¡»a (¥uhÞnl£) Ru¥ã ò‰WnehÆ‰F« Fiwªj msî 
blÞnlhÞonuh‹ Ru¥ã ÚU¡F« cŸs bjhl®ig f©l¿í« MuhŒ¢á¡F 
njitahd mid¤J Étu§fisí« bjÇa¥gL¤Jtj‰F eh‹ KGr«kj« 
bjÇÉ¡»nw‹.  
ïªj MuhŒ¢áÆš ãwÇ‹ Ã®gªjÄ‹¿ v‹ brhªj ÉU¥g¤â‹ngÇš 
g§F bgW»‹nw‹. ïªj MuhŒ¢áÆš ïUªJ eh‹ vªneuK« 
ã‹th§fyh« v‹gijí« mjdhš vªj ghâ¥ò« V‰glhJ v‹gijí« 
eh‹ òÇªJbfh©nl‹. 
R¡»a (¥uhÞnl£) Ru¥ã ò‰WnehÆ‰F« Fiwªj msî 
blÞnlhÞonuh‹ Ru¥ã ÚU¡F« cŸs bjhl®ig f©l¿í« MuhŒ¢á 
g‰¿a jftš jhis eh‹ bg‰W¡ bfh©nl‹.  
ïªj MuhŒ¢áÆdhš V‰gL« e‹ikfisí«, áy 
g¡fÉisîfisí« g‰¿ bjËthf kU¤Jt® _y« bjÇªJ bfh©nl‹. 
eh‹ v‹Dila Ra ÃidîlD« k‰W« KG Rjªâu¤JlD« ïªj 
kU¤Jt MuhŒ¢áÆš v‹id nr®¤J¡bfhŸs r«kj«. 
 
................................ 
nehahËÆ‹ bga® 
................................ 
ifbah¥g«/ ïlJ bgUÉuš nuif 
............................  
njâ 
 
 
  
   
................................ 
MuhŒ¢áahsÇ‹ 
bga® 
................................ 
ifbah¥g« 
............................  
njâ 
 MuhŒ¢á jftš jhŸ 
br‹id ïuhé›fhªâ muR bghJ kU¤JtidÆš, R¡»a 
(¥uhÞnl£) Ru¥ã ò‰WnehÆ‰F« Fiwªj msî blÞnlhÞonuh‹ Ru¥ã 
ÚU¡F« cŸs bjhl®ig f©l¿í« MuhŒ¢á ï§F eilbg‰W tU»‹wJ.   
Ú§fS« MuhŒ¢áÆš g§nf‰f eh§fŸ ÉU«ò»nwh«. ïªj 
MuhŒ¢áÆš j§fË‹ nfŸÉfŸ nf£fg£L mj‹ jftšfisí« 
Koîfisí« MuhŒnth«. mjdhš j§fŸ á»¢ir¡F v›Éj ghâ¥ò« 
V‰glhJ v‹gij bjÇÉ¤J¡ bfhŸ»nwh«.  
ïªj MuhŒ¢áÆ‹nghJ j§fËlÄUªJ clšeygÇnrhjid¡F 
njitahd ïu¤j« vL¡F«nghJ ïªj blÞnlhÞonuh‹ Ru¥ã Ú® 
f©l¿a njitahd ïu¤j« vL¡fgL« v‹gijí«, mjdhš v›Éj 
ghâ¥ò« V‰glhJ v‹gij bjÇÉ¤J¡ bfhŸ»nwh«.  
Koîfis mšyJ fU¤Jfis btËÆL«nghnjh mšyJ 
MuhŒ¢áÆ‹ nghnjh j§fsJ bgaiunah mšyJ milahs§fisnah 
btËÆlkh£nlh« v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj MuhŒ¢áÆš g§nf‰gJ j§fSila ÉU¥g¤â‹ ngÇš jh‹ 
ïU¡»wJ. nkY« Ú§fŸ vªneuK« ïªj MuhŒ¢áÆÈUªJ ã‹th§fyh« 
v‹gijí« bjÇÉ¤J¡ bfhŸ»nwh«. 
ïªj áw¥ò gy‹fis/ Koîfis MuhŒ¢áÆ‹nghJ mšyJ 
MuhŒ¢áÆ‹ KoÉ‹ nghJ j§fS¡F m¿É¥ngh« v‹gijí« 
bjÇÉ¤J¡ bfhŸ»nwh«. 
 
 
 
-------------------------    ------------------------- 
MuhŒ¢áahs® ifbah¥g«   g§nf‰ghs® ifbah¥g« 
njâ: 
 
INFORMATION TO PARTICIPANTS 
 
SPONSOR : NIL 
Investigator: Dr.K. ARUNPRASAD 
  
Name of Participant: 
Title:  “A study of association of low serum testosterone and prostate cancer 
behaviour” 
 
You are invited to take part in this study. The information in this document is 
meant to help you decide whether or not to take part. Please feel free to ask if you 
have any queries or concerns. You are being asked to participate in this study being 
conducted in Madras Medical College and Rajiv Gandhi Government General 
Hospital  Chennai-3. 
What is the Purpose of the Research?  
1. To evaluate the relationship between low levels of hormone testosterone in 
blood and prostate cancer behaviour and  
2. To study the correlation between low levels of hormone testosterone in blood 
and tumour marker PSA. We have obtained permission from the Institutional 
Ethics Committee. 
The Study Design 
Patients: All Transrectal Ultrasound guided biopsy proven cases of prostate cancer 
with low serum testosterone level with age more than 40 years  
Control: All Transrectal Ultrasound guided biopsy proven cases of prostate cancer 
with normal serum testosterone level with age more than 40 years  
Study Procedures 
Inclusion Criteria: 
All newly diagnosed prostate cancer patients (Trans rectal ultrasound guided 
biopsy proved) in our institution will be enrolled 
Exclusion Criteria: 
• Patients already  on testosterone replacement therapy 
• Patients on other hormonal therapy 
• Patients taking medications known to lower PSA (finasteride or dutasteride) 
were excluded from this study. 
 
Possible Risks to you - Briefly Mention: Nil 
Possible benefits to you:  
The results of the study may help you in better planning of hormonal ablative 
treatment options and better patient outcome 
 
Possible benefits to other people 
The result of the research may provide benefits to the society in terms of 
advancement of medical knowledge and / or therapeutic benefits to future patient 
for better management of prostate cancer  
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, IEC and any person or agency required 
by law like the Drug Controller General of India to view your data, if required. The 
information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decisions to not participate in this research study will not affect your 
medical care or your relationship with investigator or the institution. Your doctor 
will still take care of you and you will not loose any benefits to which you are 
entitled. 
 
                         PROFORMA 
 
“A  STUDY OF ASSOCIATION OF LOW SERUM TESTOSTERONE 
AND PROSTATE CANCER BEHAVIOUR” 
 
 SL No.     :          Date : 
 
 Patient name          :                                            Age/sex :                            
 
 IP .NO                     : 
 
 Address                  :   
             
 Chief complaints     : 
 
 Presenting illness   : 
 
 
 Past medical /surgical history  : 
 
 
 Previous  H/O TRUS Biopsy    : 
 
 Personal history                       : 
 
 Family history                          :                 
 
 General  examination              : 
 
 Pulse :                                                               BP: 
 
 P/A :                                                                  E/G:                                           
 
 DRE: 
 
 
 
 
 
INVESTIGATIONS 
 
 
 HB                                                                 Urine R/E  :                                                                                                      
 TC 
 DC                                                                 Urine C&S :   
 ESR 
 
 RBS 
 
 Blood urea 
  
 Serum creatinine 
 
 Serum Electrolytes 
 
 USG KUB/TRUS 
 
 TRUS biopsy report (Gleason score)   
 
 Serum Testosterone             
 
 Serum PSA 
 
 Other findings 
   
 X-rays 
 
 Bone scan 
 
 CECT/MRI abdomen 
 
 
 
PG T N M PT PN M TGS SMS ECE SVI
1 DHAKSHINAMOORTHY 60/M 56829 24.06 4 4 8 193.6 T3A N1 M1B HORMONAL
2 ARJUNAN 55/M 56013 21.7 3 3 6 656.4 T2A N0 M1B HORMONAL
3 BOOPALAN 55/M 62037 18.2 4 4 8 173.2 T3B N0 M0 HORMONAL
4 JANARTHANAN 68/M 67907 31.8 3 3 6 443.1 T2A N0 M1A HORMONAL
5 SANDHYAGU 58/M 56621 25.9 3 4 7 674.6 T3B N0 M0 HORMONAL
6 ARJUN 55/M 51080 28.6 3 3 6 492.3 T3A N1 M0 HORMONAL
7 RAJAMANI 45/M 35806 11.8 3 3 6 640.8 T3B N0 M0 HORMONAL
8 GOVINDHAN 78/M 27747 26.7 3 4 7 723.4 T2B N0 M1B HORMONAL
9 ETHIRAJ 68/M 31168 14.6 4 4 8 187.4 T2B N0 M0 RP PT3B PN1 M0 8 N P P
10 IBRAHIM SHERIFF 70/M 51168 16.2 3 3 6 447.8 T3A N1 M0 HORMONAL
11 KUMAR 52/M 58723 12.6 3 3 6 654.3 T3B N0 M0 HORMONAL
12 KRISHNAN 75/M 22513 7.1 3 3 6 411.3 T3B N0 M0 HORMONAL
13 PADMANABAN 85/M 39505 26.4 3 4 7 387.1 T2C N1 M0 HORMONAL
14 KRISHNAN 60/M 89016 82.4 4 5 9 146.4 T3B N1 M1C HORMONAL
15 ARUNAGIRI 68/M 67221 21.7 3 3 6 512.3 T2A N0 M1B HORMONAL
16 KUPPUSAMY 65/M 14043 15.3 3 3 6 437.1 T3A N0 M0 HORMONAL
17 GOPAL 60/M 14043 18.4 3 3 6 816.1 T3B N0 M0 HORMONAL
18 PAULRAJ 65/M 65918 31.9 4 4 8 157.6 T3B N1 M1B HORMONAL
19 PERUMAL 60/M 50979 11.2 4 5 9 142.7 T2A N0 M0 RP PT3B PN1 M0 10 P P P
20 KRISHNAN 61/M 28148 25.4 3 3 6 776.1 T3A N0 M1B HORMONAL
21 VAIYABURI 76/M 95813 19.4 3 4 7 694.6 T3B N0 M0 HORMONAL
22 KRISHNAMOORTHY 64/M 90427 28.4 3 4 7 590.6 T2B N0 M1B HORMONAL
23 VEERASAMY 70/M 12179 9.1 3 4 7 394.5 T2B N0 M0 RP PT2B PN0 M0 7 N N N
24 JEYAKUMAR 74/M 25367 8.6 3 3 6 647.4 T3A N0 M0 HORMONAL
25 PULLAIAH 70/M 19081 43.8 4 4 8 173.6 T3B N1 M1B HORMONAL
26 ANBAZHAGAN 59/M 15432 21.2 3 4 7 594.3 T2A N0 M1B HORMONAL
27 KRISHNAKUMAR 75/M 14309 24.3 3 4 7 137.4 T3A N1 M1B HORMONAL
28 JEYACHANDRAN 65/M 12006 29.8 3 3 6 347.7 T2B N0 M1B HORMONAL
29 DURAI 58/M 11032 31.2 4 4 8 164.3 T2B N0 M1B HORMONAL
30 ABDULATEEF 62/M 12015 33.1 3 3 6 540.1 T2A N0 M1B HORMONAL
31 KRISHNAMOORTHY 74/M 61479 28.6 4 4 8 153.4 T2B N1 M0 HORMONAL
32 MUNUSAMY 68/M 24498 13.6 4 3 7 497.6 T3A N0 M0 HORMONAL
33 DHAKSHINAMOORTHY 70/M 56826 11.6 3 3 6 461.2 T3B N0 M0 RP PT2B PN0 M0 7 N N N
34 APPARAO 75/M 11864 51.4 5 5 10 86.8 T4A N1 M1C HORMONAL
35 RAJAN 63/M 81610 16.8 3 3 6 467.4 T3A N1 M0 HORMONAL
36 KOTHANDARAMAN 85/M 13086 25.4 3 4 7 541.6 T3B N0 M0 HORMONAL
37 SUNDARRAJ 57/M 11847 14.3 4 3 7 379.1 T3B N0 M0 HORMONAL
38 DURAI 56/M 16025 14.6 3 4 7 297.2 T3A N0 M0 HORMONAL
39 PATTU 51/M 10881 28.7 5 4 9 100.4 T3B N1 M1B HORMONAL
40 ELUMALAI 55/M 53201 26.3 4 4 8 391.3 T3A N0 M0 HORMONAL
41 VENUGOPAL 46/M 58902 5.2 4 4 8 119.4 T2B N0 M0 RP PT3B PN1 M0 9 P P P
42 VARADHAN 48/M 98964 19.4 3 4 7 641.1 T3B N0 M0 HORMONAL
43 SAMINATHAN 58/M 95006 16.1 3 3 6 520.3 T3B N0 M0 HORMONAL
Pathological 
Stage
Clinical Stage
Serum PSA TGS
Serum 
Testostrone
SGSl no. Name Age/Sex IP no MANAGEMENT
PG T N M PT PN M TGS SMS ECE SVI
Pathological 
Stage
Clinical Stage
Serum PSA TGS
Serum 
Testostrone
SGSl no. Name Age/Sex IP no MANAGEMENT
44 RAMAMOORHTY 56/M 10634 7.8 3 4 7 418.2 T3B N0 M0 HORMONAL
45 SUBRAMANI 58/M 18990 24.3 4 4 8 396.9 T3A N0 M1B HORMONAL
46 SELVAM 60/M 98813 36.7 4 4 8 117.2 T4A N1 M1B HORMONAL
47 JEYARAMAN 74/M 94990 13.2 3 4 7 294.3 T3A N0 M0 HORMONAL
48 GOVINDASAMY 70/M 96230 15.4 4 3 7 397.1 T3A N0 M0 HORMONAL
49 ISMAIL 66/M 34266 11.6 3 3 6 647.3 T2B N0 M0 RP PT2B PN0 M0 7 N N N
50 SENGAPPAN 65/M 30054 13.6 4 3 7 384.6 T3B N0 M0 HORMONAL
51 SUNDARAM 68/M 10410 17.9 3 3 6 446.4 T3A N0 M0 HORMONAL
52 RAMAKRISHNAN 70/M 18910 28.2 3 4 7 720.4 T2B N1 M1B HORMONAL
53 CHANDRAMOHAN 65/M 10517 36.4 4 3 7 477.4 T2B N0 M1B HORMONAL
54 CHINNASAMY 62/M 11296 13.1 3 4 7 399.1 T3B N0 M0 HORMONAL
55 PADAMANABAN 64/M 62596 43.4 4 5 9 148.4 T3B N1 M1B HORMONAL
56 KALIYAPPAN 57/M 96721 9.4 4 3 7 794.3 T3A N0 M0 HORMONAL
57 JEYACHANDRAN 62/M 89426 34.2 4 4 8 543.4 T3B N1 M0 HORMONAL
58 RAJANGAM 62/m 61223 56.2 5 4 9 139.4 T4B N1 M1C HORMONAL
59 LOGANATHAN 50/M 10789 18.6 3 4 7 364.8 T3A N0 M0 HORMONAL
60 SIVARAMAN 62/M 11083 11.4 3 3 6 561.6 T3B N0 M0 HORMONAL
61 PERUMAL 68/M 10523 8.6 3 3 6 399.6 T3A N0 M0 HORMONAL
62 PONNUSAMY 55/M 11957 14.7 4 3 7 129.6 T2B N0 M0 RP PT2B PN0 M0 8 N N N
63 SUBRAMANI 64/M 20542 14.3 3 4 7 467.6 T3B N0 M0 HORMONAL
64 GOVINDHAN 61/M 50812 26.5 4 4 8 100.4 T3B N1 M0 HORMONAL
65 ALLIAPPAN 75/M 16905 26.4 3 4 7 764.3 T3B N0 M0 HORMONAL
66 HAMEED 65/M 15063 13.6 4 4 8 593.6 T3A N0 M0 HORMONAL
67 PAMMAL 65/M 69110 6.8 3 3 6 654.6 T2B N0 M0 HORMONAL
68 RAJI GOUNDER 50/M 50662 13.9 3 3 6 344.6 T3A N0 M0 HORMONAL
69 CHENGALRAJ 48/M 41438 11.6 3 4 7 651.6 T3B N0 M0 HORMONAL
70 KUMAIYAN 68/M 43508 7.4 3 3 6 721.3 T3B N0 M0 HORMONAL
71 RATHINAM 65/M 27764 23.4 3 3 6 495.3 T3A N1 M0 HORMONAL
72 RAGHAVAN 69/M 74810 12.6 3 4 7 394.4 T2A N0 M0 RP PT2B PN0 M0 7 N N N
73 DIWAKARAN 74/M 29081 12.4 4 3 7 711.4 T2B N0 M0 HORMONAL
74 ROSE NAIDU 82/M 10639 96.4 4 4 8 48.3 T4B N1 M1B HORMONAL
75 VENKATACHALAM 64/M 11063 8.4 3 3 6 621.4 T3B N0 M0 HORMONAL
76 PALANIYAPPAN 70/M 18612 16.2 3 4 7 576.4 T3B N0 M0 HORMONAL
77 KUMAR 59/M 72610 16.3 4 3 7 384.6 T3A N1 M0 HORMONAL
78 PURUSHOTHAMAN 64/M 50782 8.4 3 3 6 396.4 T3A N0 M0 HORMONAL
79 ANANDHAN 66/M 41487 37.1 4 3 7 212.6 T2C N1 M1B HORMONAL
80 NATARAJAN 72/M 23112 24.8 4 3 7 716.4 T3B N0 M0 HORMONAL
81 GANESAN 75/M 34278 6.5 3 3 6 427.4 T3A N0 M0 HORMONAL
82 KRISHNAN 65/M 22178 14.7 4 3 7 154.6 T2B N0 M0 RP PT3A PN1 M0 9 P P N
83 BALASUNDARAM 85/M 10759 17.6 3 3 6 347.4 T3A N0 M0 HORMONAL
84 SUBBARAYAN 70/M 91404 13.4 4 3 7 459.4 T3B N0 M0 HORMONAL
85 MURUGAVEL 65/M 27891 18.6 3 4 7 724.4 T3A N0 M0 HORMONAL
86 PALANI KUMAR 71/M 74213 9.3 3 3 6 436.4 T3B N0 M0 HORMONAL
PG T N M PT PN M TGS SMS ECE SVI
Pathological 
Stage
Clinical Stage
Serum PSA TGS
Serum 
Testostrone
SGSl no. Name Age/Sex IP no MANAGEMENT
87 ABDUL MAJITH 56/M 83049 24.3 4 4 8 174.6 T2C N1 M1B HORMONAL
88 RAMAKRISHNAN 62/M 56190 21.6 3 3 6 556.4 T3A N0 M0 HORMONAL
89 PREM PRASAD 51/M 47838 26.4 4 3 7 636.4 T3B N0 M0 HORMONAL
90 SUNDARAM 46/M 50610 21.2 3 3 6 394.6 T2C N1 M0 HORMONAL
91 MUTHUPANDI 59/M 56998 13.6 3 4 7 439.6 T2B N0 M0 RP PT3A PN0 M0 8 N P N
92 VELAYUDHAM 75/M 50670 12.4 3 4 7 712.4 T3B N0 M0 HORMONAL
93 SUBBAIAH 82/M 60835 21.4 4 3 7 556.4 T2C N0 M0 HORMONAL
94 SUBRAMANI 60/M 83176 7.6 4 3 7 396.8 T2A N0 M0 RP PT2B PN0 M0 8 N N N
95 ESWARAN 65/M 59436 9.4 3 4 7 394.3 T3B N0 M0 HORMONAL
96 VENKATESAN 69/M 28756 19.2 4 3 7 431.6 T3B N0 M0 HORMONAL
97 MUNUSAMY 70/M 84782 26.2 4 4 8 168.6 T3B N1 M0 HORMONAL
98 DURAI KANNAN 70/M 89614 8.2 3 3 6 374.4 T3B N0 M0 HORMONAL
99 VELLAI 65/M 84381 21.4 3 4 7 398.6 T3A N0 M1B HORMONAL
100 RAMAN 60/M 96242 7.6 3 3 6 347.3 T3B N0 M0 HORMONAL
T-TUMOUR PT-PTHOLOGICAL TUMOUR SMS-SURGICAL MARGIN STATUS RP-RADICAL PROSTATECTOMY
N-NODAL STATUS PN-PATHOLOGICAL NODE ECE-EXTRA CAPSULAR EXTENSION P-POSITIVE
M-METASTASIS SVI-SEMINAL VESICAL INVATION N-NEGATIVE
PG-PRIMARY GLEASON SCORE
SG-SECONDARY GLESON SCORE
TGS-TOTAL GLEASON SCORE
ABBREVIATIONS
LIST OF ABBRIEVIATIONS 
 
PSA- Prostate specific antigen 
DRE- Digital rectal examination 
TRUS- Transrectal ultrasonography 
TGS- Total Gleason score 
CT- Clinical tumour status 
CN-Clinical nodal status 
M- Metastasis 
PT- pathological tumour status 
PN- Pathological nodal status 
ECE- Extra capsular extension 
SMS- Surgical margin status 
SVI- Seminal Vesical invasion 
BPH - Benign prostatic hyperplasia   
LUTS - lower urinary tract symptoms 
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